Frontlight ResearchEarly access
CompletedPhase 3
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
Key facts
- Who runs it
- Centers for Disease Control and Prevention
- Where
- Peru2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 192 people enrolled
- Started
- 4 Nov 2022
- Ended
- 4 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- FLUAD Quadrivalent
- FluQuadri
- Record updated
- 19 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ≥18 years old
- Have participated in the healthcare personnel cohort study at Hospital Nacional Cayetano Heredia or Hospital Nacional Arzobispo Loayza during 2016-2021
- Work at the facility full-time (≥30 hours per week)
- Have routine, direct, hands-on or face-to-face contact with patients (≤1 meter) as part of a typical work shift, including, but not limited to, physicians, nurses, respiratory therapists, physical therapists, unit clerks, radiograph technicians, medical assistants, and transporters
- Work at the facility for ≥1 year prior to enrollment and planning to continue working at the facility for one year after enrollment
- Willing to receive influenza vaccination (adjuvanted or standard dose)
- Women of childbearing age must complete the following criteria to be eligible:; Have a negative urine pregnancy test performed by the study staff ≤24 hours preceding receipt of the vaccine; Be willing to use a reliable form of contraception approved by the Investigator for ≤2 months after receiving the vaccine. If they are not currently using an approved contraceptive, study staff will provide access to contraceptives; Must not be breastfeeding
Who cannot take part
- Have received a vaccine against influenza during the 2022 influenza season (season of clinical trial)
- Received blood or blood products within 3 months of enrollment
- Have a severe, life-threatening allergy to influenza vaccines, eggs, or influenza vaccine components
- Have a history of Guillain-Barre Syndrome or other autoimmune diseases
- Be pregnant, confirmed by rapid pregnancy test
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, double-blinded trial will assess humoral immune responses to adjuvanted, egg-based quadrivalent influenza vaccines compared to standard dose, egg-based quadrivalent influenza vaccines among healthcare personnel (HCP). The trial will be conducted at two sites in Lima, Peru during 2022 and 2023.
The 2 groups in the trial
- FLUAD QuadrivalentTreatment being tested
Participants administered a single dose of adjuvanted egg-based quadrivalent influenza vaccine (FLUAD Quadrivalent by Seqirus, 15 µg of HA from each strain).
- FluQuadriExisting treatment, for comparison
Participants administered a single dose of standard dose egg-based quadrivalent influenza vaccine (FluQuadri by Sanofi-Pasteur, 15 µg of HA from each strain).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel (EDUCATE)
- Publications
- Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026
- Record updated
- 19 May 2026